PD1-11 ASSOCIATION OF ERYTHROPOIETIN (EPO) GENE RS576236 POLYMORPHISM AND RISK OF ADRENAL TUMOR IN A CHINESE POPULATION

INTRODUCTION AND OBJECTIVES: Erythropoietin (EPO) is a circulating glycosylated protein hormone, which plays an important role in diseases related to anemia, as well as in the development and progression of non-hematopoietic tissue tumors. Genetic polymorphisms in EPO have been shown to influence an individualis susceptibility to cancer. The objective of the present study was to determine if the EPO rs576236 polymorphism could be associated with the risk of adrenal tumor. METHODS: We genotyped the EPO rs576236 polymorphism in a case-control study of 288 adrenal tumor patients and 456 cancer-free controls by using the TaqMan method, and assessed the association between the polymorphism and the adrenal tumor risk by logistic regression. 95% confidence interval [CI] was used to assess the genetic association between the polymorphism and the risk of adrenal tumor. RESULTS: Compared with TT genotype, the TC genotype had a significant increased adrenal tumor (adjusted odds ratio (OR) 1⁄4 1.24, 95% confidence interval [CI] 1⁄4 1.12-2.22), Furthermore a significant increased risk of adrenal tumor was found in the combined variant genotypes TC+CC compared with the TT genotype (adjusted OR 1⁄4 1.17, 95%CI 1⁄4 1.12-2.21). CONCLUSIONS: Our present study suggests that the rs576236 polymorphism in EPO confer susceptibility to adrenal tumor in the Chinese population.